I pretty much agree with all you said. The market being what it...

I pretty much agree with all you said. The market being what it is, though, a decent set of new assays should attract some buying. Hopefully they'll arrive this month. I doubt they'll get the Scoping Study complete in the next eight weeks but miracles can happen I suppose. That document will be very interesting to read and IF it indicates a viable option we might get a re-rating of sorts. The MC is very low so there has to be some scope as long as the market can believe the viability. I think I'd settle for Morningstar's valuation of 58c, though their figures are as useless as tits on a bull. Let's hope for the best. Maybe they can come up with something that induces some Chinese mob to buy us out.